BioRestorative Therapies Files 8-K with Presentation Materials
Ticker: BRTX · Form: 8-K · Filed: Mar 12, 2024 · CIK: 1505497
Sentiment: neutral
Topics: 8-K, presentation-materials, filing
Related Tickers: BRTX
TL;DR
BRTX filed an 8-K with presentation materials, no major news yet.
AI Summary
On March 11, 2024, BioRestorative Therapies, Inc. filed an 8-K report. The filing primarily concerns the presentation materials related to the company's business. No specific financial figures or significant events like acquisitions or new product launches were detailed in the provided excerpt.
Why It Matters
This filing indicates the company is providing updated information or materials to stakeholders, which could offer insights into their current strategy or business developments.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for presentation materials and does not contain information that inherently increases risk.
Key Players & Entities
- BioRestorative Therapies, Inc. (company) — Registrant
- March 11, 2024 (date) — Date of Report
- Nevada (jurisdiction) — State of incorporation
- 40 Marcus Drive Melville, New York 11747 (address) — Principal executive offices
- ( 631 ) 760-8100 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by BioRestorative Therapies, Inc.?
The primary purpose of this 8-K filing is to report presentation materials related to the company's business, as indicated by the 'ITEM INFORMATION: Regulation FD Disclosure' and 'ITEM INFORMATION: Financial Statements and Exhibits' sections.
When was this 8-K report filed?
This 8-K report was filed on March 12, 2024, and the date of the earliest event reported is March 11, 2024.
What is the exact name of the registrant?
The exact name of the registrant is BioRestorative Therapies, Inc.
Where are BioRestorative Therapies, Inc.'s principal executive offices located?
BioRestorative Therapies, Inc.'s principal executive offices are located at 40 Marcus Drive, Melville, New York 11747.
Does the filing mention any specific financial results or significant corporate actions?
Based on the provided excerpt, the filing primarily concerns presentation materials and does not detail specific financial results or significant corporate actions.
Filing Stats: 670 words · 3 min read · ~2 pages · Grade level 11 · Accepted 2024-03-12 07:30:25
Filing Documents
- form8k.htm (8-K) — 25KB
- ex99_1.htm (EX-99.1) — 8KB
- ex99_2.htm (EX-99.2) — 12KB
- image00001.jpg (GRAPHIC) — 3KB
- pm_1.jpg (GRAPHIC) — 592KB
- pm_2.jpg (GRAPHIC) — 1182KB
- pm_3.jpg (GRAPHIC) — 513KB
- pm_4.jpg (GRAPHIC) — 539KB
- pm_5.jpg (GRAPHIC) — 374KB
- pm_6.jpg (GRAPHIC) — 486KB
- pm_7.jpg (GRAPHIC) — 453KB
- pm_8.jpg (GRAPHIC) — 438KB
- pm_9.jpg (GRAPHIC) — 503KB
- pm_10.jpg (GRAPHIC) — 523KB
- pm_11.jpg (GRAPHIC) — 446KB
- pm_12.jpg (GRAPHIC) — 452KB
- pm_13.jpg (GRAPHIC) — 619KB
- pm_14.jpg (GRAPHIC) — 712KB
- pm_15.jpg (GRAPHIC) — 517KB
- pm_16.jpg (GRAPHIC) — 373KB
- pm_17.jpg (GRAPHIC) — 411KB
- pm_18.jpg (GRAPHIC) — 649KB
- pm_19.jpg (GRAPHIC) — 366KB
- pm_20.jpg (GRAPHIC) — 378KB
- pm_21.jpg (GRAPHIC) — 605KB
- pm_22.jpg (GRAPHIC) — 571KB
- pm_23.jpg (GRAPHIC) — 401KB
- pm_24.jpg (GRAPHIC) — 449KB
- pm_25.jpg (GRAPHIC) — 541KB
- pm_26.jpg (GRAPHIC) — 254KB
- pm_27.jpg (GRAPHIC) — 666KB
- pm_28.jpg (GRAPHIC) — 491KB
- pm_29.jpg (GRAPHIC) — 412KB
- pm_30.jpg (GRAPHIC) — 561KB
- 0001021771-24-000068.txt ( ) — 21488KB
- brtx-20240311.xsd (EX-101.SCH) — 4KB
- brtx-20240311_lab.xml (EX-101.LAB) — 22KB
- brtx-20240311_pre.xml (EX-101.PRE) — 16KB
- form8k_htm.xml (XML) — 4KB
01
Item 7.01 Regulation FD Disclosure . On March 11, 2024, BioRestorative Therapies, Inc. (the "Company") issued a press release (the "Press Release") announcing that the Company will be participating at the 36 th Annual ROTH Conference being held March 17 to 19, 2024 at the Ritz Carlton, Laguna Niguel, Dana Point, California. A copy of the Press Release is furnished as Exhibit 99.1 hereto. At the conference, Lance Alstodt, the Company's Chief Executive Officer, is scheduled to participate in a fireside chat. Certain presentation materials (the "Presentation Materials") may be utilized in connection with the chat. A copy of the Presentation Materials is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The Company may use the Presentation Materials, possibly with modification, in other presentations to current and potential investors, lenders, creditors, insurers, vendors, customers, employees and others with an interest in the Company and its business. The information referenced under this Item 7.01 (including Exhibits 99.1 and 99.2 referenced in Item 9.01 below) of this Current Report on Form 8-K is being "furnished" under "Item 7.01. Regulation FD Disclosure" and, as such, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information set forth in this Current Report on Form 8-K (including Exhibits 99.1 and 99.2 referenced in Item 9.01 below) shall not be incorporated by reference into any registration
Financial Statements and Exhibits
Financial Statements and Exhibits . (d) Exhibits . Number Description 99.1 Press release, dated March 11, 2024, issued by BioRestorative Therapies, Inc. 99.2 Presentation Materials 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIORESTORATIVE THERAPIES, INC. Dated: March 12, 2024 By: /s/ Lance Alstodt Lance Alstodt President and CEO